Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

IMD in South Africa: Provincial Analysis and National Trends

Current analysis of Invasive Meningococcal Disease (IMD) trends in South Africa, featuring provincial statistics, seasonal patterns, and mortality rates. Highlights significant 53% increase in cases from 2022 to 2023, with special focus on Western Cape's higher incidence rates and nationwide surveillance data from GERMS-SA programme.

Číst více

Meningococcal ACWY Vaccines: Evolution from Polysaccharide to Conjugate Technology

Comprehensive overview of meningococcal vaccines targeting serogroups A, C, W, and Y, detailing the evolution from polysaccharide vaccines with limitations to superior conjugate vaccines. Includes clinical evidence of immunological hyporesponsiveness in polysaccharide vaccines and the dramatic disease reduction achieved through conjugate vaccine implementation, particularly in Africa's meningitis belt.

Číst více

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

SULIQUA - Uproszczenie Schematu Leczenia Cukrzycy.

Zapraszamy do zapoznania się z materiałem prezentującym SULIQUA® - innowacyjne rozwiązanie w leczeniu cukrzycy typu 2. Dowiedz się, jak można uprościć schemat leczenia, poprawić kontrolę glikemii i zredukować ryzyko hipoglikemii przy jednym wstrzyknięciu dziennie. Materiał zawiera kluczowe informacje o skuteczności terapii i jej wpływie na jakość życia pacjentów.

Číst více

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 5 of 10: The benefits of early combination therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 8 of 10: Benefits of early combination therapy of GLP-1 and basal

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více

Part 9 of 10: Benefits of a second-generation basal insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Číst více